Maresin 2 是一种抗炎和促消退介质,它通过激活原代人肠道上皮细胞中的局灶性细胞-基质黏附信号通路驱动肠道上皮细胞迁移,从而促进黏膜伤口修复,通过抑制 IL-1β 减轻 1 型糖尿病大鼠脊髓和前额叶皮层的伤害性及焦虑样行为,通过抑制 NLRP3 炎症小体的激活、Th2 型免疫反应和氧化应激减轻小鼠过敏性气道炎症,抑制炎症性和神经性三叉神经痛并降低三叉神经节的神经元激活,以及促进炎症消退、DSS 诱导的结肠炎或活检诱导的结肠黏膜损伤后的黏膜修复。
产品编号: MS-E91467 纯度: 97.2% CAS No.: 1639809-46-3 分子式: C22H32O4 分子量: 360.49
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10μg (277.4μM * 100μL in Ethanol)
询价
3-5 天

产品描述

Maresin 2 是一种抗炎和促消退介质,它通过激活原代人肠道上皮细胞中的局灶性细胞-基质黏附信号通路驱动肠道上皮细胞迁移,从而促进黏膜伤口修复,通过抑制 IL-1β 减轻 1 型糖尿病大鼠脊髓和前额叶皮层的伤害性及焦虑样行为,通过抑制 NLRP3 炎症小体的激活、Th2 型免疫反应和氧化应激减轻小鼠过敏性气道炎症,抑制炎症性和神经性三叉神经痛并降低三叉神经节的神经元激活,以及促进炎症消退、DSS 诱导的结肠炎或活检诱导的结肠黏膜损伤后的黏膜修复。

生物实验数据

生物活性 Maresin 2 is an anti-inflammatory and pro-resolving mediator that promotes mucosal wound repair by driving intestinal epithelial cell migration through activation of focal cell-matrix adhesion signaling pathways in primary human intestinal epithelial cells, alleviates nociceptive and anxiety-like behaviors in the spinal cord and prefrontal cortex of type 1 diabetic rats by inhibiting IL-1β, attenuates allergic airway inflammation in mice by inhibiting NLRP3 inflammasome activation, Th2-type immune responses, and oxidative stress, suppresses inflammatory and neuropathic trigeminal pain and reduces neuronal activation in the trigeminal ganglion, and promotes inflammation resolution and mucosal repair following DSS-induced colitis or biopsy-induced colonic mucosal injury.
IC50 & Target

NLRP3 inflammasome

 

IL-1β

 

体外研究
(In Vitro)

Maresin 2 (200 nM) 与 10 ng/mL TNFα/IFNγ 联合作用时,可促进 HT29/B6 肠上皮细胞的划痕伤口愈合及迁移效率。
Maresin 2 (200 nM; 16 h) 与 10 ng/mL TNFα/IFNγ 联合作用时,可激活 HT29/B6 肠上皮细胞中的 FAK-Src-paxillin 和 talin-vinculin 黏着斑信号轴,促进伤口前缘的促迁移信号传导。

Immunofluorescence

Cell Line: HT29/B6 human intestinal epithelial cells
Concentration: 200 nM
Incubation Time: 16 h
Result: Increased numbers of vinculin-containing focal adhesions at the leading edge of spreading cells significantly relative to TNFα/IFNγ alone (P < 0.01).
体内研究
(In Vivo)

Maresin 2 (2 ng/g body weight;腹腔注射;单次;创伤后 24 h) 在 C57BL/6 小鼠活检诱导的结肠黏膜损伤模型中,可显著将损伤后 72 h 的结肠黏膜伤口愈合率提升至 47.67%。
Maresin 2 (2 ng/g body weight;腹腔注射;于第 0、2、4、6 和 8 天给予;5 次) 可显著降低 5% DSS 诱导的 C57BL/6 小鼠结肠炎模型的疾病活动度及结肠黏膜损伤,组织学结肠炎评分为 3.951。
Maresin 2 (每只大鼠 1-10 ng;腹腔注射;连续 2 天每日给予,随后隔日给予;链脲佐菌素诱导后第 14-32 天) 可显著缓解链脲佐菌素诱导的雄性 Wistar 糖尿病大鼠的机械性痛觉过敏 (剂量为 1、3 和 10 ng/rat 时),并在剂量为 3 ng/rat 时改善其焦虑样行为,同时可使脊髓和前额叶皮层中的 IL-1β 水平恢复正常。
Maresin 2 (每只小鼠 1 ng;静脉注射;共 4 天) 对卵清蛋白诱导的雌性 BALB/c 小鼠哮喘具有保护作用,可减轻气道炎症、Th2 免疫应答、NLRP3 炎症小体活化及氧化应激。
Maresin 2 (1-10 ng;髓蛛网膜下腔;单次注射) 可显著减轻大鼠福尔马林诱导的口面部伤害感受的急性期和炎症期。
Maresin 2 (10 ng;术后第 1 天和第 3 天共注射 2 次) 可在大鼠术后口面部疼痛模型中阻止热痛觉过敏和机械痛觉过敏的发生。

Animal Model: C57BL/6 (10 to 12 weeks old, male and female, biopsy-induced colonic mucosal injury)
Dosage: 2 ng/g body weight
Administration: i.p.; single injection; 24 h post-wounding
Result: Increased colonic mucosal wound healing to 47.67% at 72 h post-wounding compared to 34.58% in vehicle control mice (P < 0.01).
Animal Model: C57BL/6 (10 to 12 weeks old, male and female, 5% DSS-induced colitis)
Dosage: 2 ng/g body weight
Administration: i.p.; 5 doses on days 0, 2, 4, 6, and 8
Result: Reduced disease activity index (DAI) scores at multiple time points (P < 0.01, P < 0.001, P < 0.0001).
Reduced histological colitis score to 3.951 compared to 5.474 in vehicle control mice (P < 0.05).
Decreased mucosal ulceration/erosion and infiltrating immune cells.
Animal Model: Wistar rats (male, 180-240 g, streptozotocin-induced type 1 diabetes mellitus)
Dosage: 1 ng/rat; 3 ng/rat; 10 ng/rat
Administration: i.p.; daily for 2 consecutive days, then alternate days; days 14-32 post-streptozotocin induction
Result: Failed to alter mechanical threshold in diabetic rats after acute treatment.
Showed significant improvement in mechanical threshold at 3 ng dose on day 20 post-streptozotocin induction (p = 0.0017).
Showed significant improvement in mechanical threshold at all doses (1, 3, 10 ng) on day 26 post-streptozotocin induction (p < 0.05) compared to vehicle-treated diabetic rats.
Significantly increased time spent in open arms (p = 0.05) and decreased time spent in closed arms (p < 0.05) in elevated plus-maze test at 3 ng dose compared to vehicle-treated diabetic rats.
Did not alter depressive-like behavior in modified forced swimming test or locomotor/exploratory behavior in open-field test at any dose.
Reversed elevated IL-1β levels in spinal cord at 3 ng (p = 0.0170) and 10 ng (p = 0.0445) doses compared to vehicle-treated diabetic rats.
Reversed elevated IL-1β levels in prefrontal cortex at all doses (1 ng, p = 0.0151; 3 ng, p = 0.0266; 10 ng, p = 0.0201) compared to vehicle-treated diabetic rats.
Did not affect IL-1β levels in hippocampus, hyperglycemia, or low weight gain in diabetic rats at any dose.
Animal Model: BALB/c (female, 6-8 weeks old, 20-25 g, specific pathogen-free, ovalbumin-induced asthma model)
Dosage: 1 ng per mouse
Administration: i.v.; daily; 4 days
Result: Reduced airway inflammation score (P < 0.05) and goblet cell proliferation score (P < 0.05).
Decreased lung tissue expression of MPO (P < 0.01) and Ly-6G (P < 0.05).
Lowered total inflammatory cell count (P < 0.05), neutrophil count (P < 0.05), and eosinophil count (P < 0.05) in BALF.
Reduced BALF levels of Th2 cytokines IL-4 (P < 0.01), IL-5 (P < 0.01), and IL-13 (P < 0.01).
Lowered serum total IgE (P < 0.01) and ovalbumin-specific IgE (P < 0.05).
Decreased lung tissue expression of NLRP3 (P < 0.05), ASC (P < 0.05), and Caspase-1 (P < 0.05).
Reduced BALF levels of IL-1β (P < 0.05) and IL-18 (P < 0.05).
Decreased lung tissue MDA levels (P < 0.05) and increased GSH (P < 0.05) and SOD (P < 0.01) levels.
Reduced lung tissue ICAM-1 expression (P < 0.01).
性状 液体
颜色 Colorless to light yellow

化学信息

分子量 360.49
分子式 C22H32O4
CAS No. 1639809-46-3

储存&溶解度

溶解度信息
Ethanol: 40 mg/mL (110.96 mM), Sonication is recommended.
DMSO: 40 mg/mL (110.96 mM), Sonication is recommended.
储存方式

Solution, -20°C, 2 years

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础